Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05698095 · ClinicalTrials.gov registry record · Phase 1

Pharmacokinetics, Safety, and Tolerability of Intramuscular 5-MeO-DMT in Healthy Volunteers

A Phase 1 study, sponsored by Usona Institute.

Completed
Registry status
Phase 1
Development phase
54
Enrollment target

NCT05698095 is a Phase 1 study that has completed, run by Usona Institute. The registered enrollment target is 54 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05698095, a Phase 1 study, has completed, sponsored by Usona Institute.

COMPLETED
Registry status
Phase 1
Development phase
54 participants
Enrollment target

Study Summary

The primary objective of the study is to assess the pharmacokinetics, safety, and tolerability of a single-dose and multiple-doses of 5-MeO-DMT administered by intramuscular (IM) injections in healthy subjects.

Interventions

  • DRUG Placebo
  • DRUG 5-methoxy-N,N-dimethyltryptamine succinate salt

Trial Details

FieldValue
Enrollment Target 54 participants
Start Date 2022-12-27
Est. Completion 2023-09-07
Phase Phase 1

Sponsor

Usona Institute

5 total trials

What the Registry Record Tells You About NCT05698095

The ClinicalTrials.gov registry entry for NCT05698095 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Usona Institute, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT05698095 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT05698095 about?

NCT05698095 is a clinical study titled "Pharmacokinetics, Safety, and Tolerability of Intramuscular 5-MeO-DMT in Healthy Volunteers". The primary objective of the study is to assess the pharmacokinetics, safety, and tolerability of a single-dose and multiple-doses of 5-MeO-DMT administered by intramuscular (IM) injections in healthy subjects.

What is the current status of trial NCT05698095?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2022-12-27. Estimated completion is 2023-09-07.

What interventions are being tested in trial NCT05698095?

The interventions under investigation include: Placebo (DRUG), 5-methoxy-N,N-dimethyltryptamine succinate salt (DRUG).

Who is sponsoring clinical trial NCT05698095?

This trial is sponsored by Usona Institute, which has 5 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.